All In Biotech

Drug Trial Radar · NCT05024214

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Envafolimab(KN035) in Combination With Lenvatinib in the Treatment of Advanced Solid Tumors: a Multicenter, Open-label, Phase Ib/II Study

Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Nov 15, 2021

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors. The primary hypothesis of this study is that subjects will have a better objective response rate (ORR) when treated with Envafolimab plus Lenvatinib than SOC.

Conditions

  • Solid Tumors
  • Non-small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Hepatocellular Carcinoma

Interventions

  • Lenvatinib + EnvafolimabDrug

    Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle. Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.

  • SunitinibDrug

    Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RP2D(Phase Ib)Time frame: first Cycle (28 Days)
  2. Dose Limiting Toxicity (DLT) (Phase Ib)Time frame: first Cycle (28 Days)
  3. objective response rate (ORR) (Phase II)Time frame: Two years

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Fudan University

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

  • The Seventh Medical Center of the PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Zhongshan Hospital,Fudan University(Xiamen Branch)

    Xiamen, Fujian, China · Not yet recruiting

  • Dongguan People's Hospital

    Dongguan, Guangdong, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The Fifth Affiliated Hospital Sun Yat-Sen University

    Zhuhai, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Haerbin, Heilongjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • The Second Affiliater Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • THE First Hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Not yet recruiting

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Recruiting

  • The 960th Hospital of the PLA Joint Logistics Support Force

    Jinan, Shandong, China · Recruiting

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The Cancer Affiliated Hospital of Xinjiang Medical College

    Ürümqi, Xinjiang, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Recruiting

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.